M2R-001 is under clinical development by XCELL Medical Solutions and currently in Phase II for Muscle Injury. According to GlobalData, Phase II drugs for Muscle Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the M2R-001 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

M2R-001 overview

M2R-001 is under development for the treatment of muscle and tendon injury. The therapeutic candidate is being developed based on M2R Technology.

XCELL Medical Solutions overview

XCELL Medical Solutions operates in the pharmaceuticals and healthcare industry, specializing in the central nervous system therapy area. It focuses on developing treatments for disorders related to the central nervous system and uncontrolled inflammation. The company is headquartered in Madrid City, Madrid, Spain.

For a complete picture of M2R-001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.